Abstract
Glycoprotein (GP) IIb\IIIa receptor plays a central role on platelets activation and its blockage has been a matter of interest since the beginning of percutaneous revascularization. After first promising trials, GP IIb\IIIa inhibitors (GPI) have been widely used in cath labs for about a decade, significantly improving prognosis for patients with STSegment Elevation Myocardial Infarction (STEMI). However, their utilization isn’t exempt from risks, mainly in form of bleeding disorders, which can negatively affect patients’ outcome. Moreover, routinary administration of thyenopiridines like clopidogrel and the introduction of new anticoagulants like bivalirudin significantly reduced indications for GPI. In this review, a risk/benefit evaluation GP IIb\IIIa inhibitors is presented and their indications for STEMI patients addressed to revascularization are discussed according to recent advances reported in literature.
Keywords: STEMI, glycoprotein IIb\IIIa, abcximab, eptifibatide, tirofiban, clopidogrel, bivalirudin, anticoagulants, bleeding disorders
Current Vascular Pharmacology
Title:GP IIb/IIIa Inhibitors for STEMI: Still the Gold Standard or an Old Survivor?
Volume: 10 Issue: 4
Author(s): Giuseppe Musumeci, Matteo Baroni and Roberta Rossini
Affiliation:
Keywords: STEMI, glycoprotein IIb\IIIa, abcximab, eptifibatide, tirofiban, clopidogrel, bivalirudin, anticoagulants, bleeding disorders
Abstract: Glycoprotein (GP) IIb\IIIa receptor plays a central role on platelets activation and its blockage has been a matter of interest since the beginning of percutaneous revascularization. After first promising trials, GP IIb\IIIa inhibitors (GPI) have been widely used in cath labs for about a decade, significantly improving prognosis for patients with STSegment Elevation Myocardial Infarction (STEMI). However, their utilization isn’t exempt from risks, mainly in form of bleeding disorders, which can negatively affect patients’ outcome. Moreover, routinary administration of thyenopiridines like clopidogrel and the introduction of new anticoagulants like bivalirudin significantly reduced indications for GPI. In this review, a risk/benefit evaluation GP IIb\IIIa inhibitors is presented and their indications for STEMI patients addressed to revascularization are discussed according to recent advances reported in literature.
Export Options
About this article
Cite this article as:
Musumeci Giuseppe, Baroni Matteo and Rossini Roberta, GP IIb/IIIa Inhibitors for STEMI: Still the Gold Standard or an Old Survivor?, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812737
DOI https://dx.doi.org/10.2174/157016112800812737 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of Sirt1 and Sirt1 Modulators in Cardiovascular and Metabolic Diseases
Recent Patents on Cardiovascular Drug Discovery Patent Selections
Recent Patents on Biomarkers Preface [Hot Topic: Cytochrome P450 and Diseases: Implications in Drug Metabolism and Pathophysiology (Guest Editor: Vincent Pichette)]
Current Drug Metabolism Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets Subject Index To Volume 1
Recent Patents on Cardiovascular Drug Discovery Latest Advances in Hydrogel-Based Drug Delivery Systems for Optimization of Metabolic Syndrome Treatment
Current Medicinal Chemistry Bivalirudin: Alternative Anticoagulation During Cardiopulmonary Bypass in Patients with Heparin-Induced Thrombocytopenia
Recent Patents on Cardiovascular Drug Discovery Sigma-1 Receptor Chaperones and Diseases
Central Nervous System Agents in Medicinal Chemistry Reduction in the Ratio of Low-density Lipoprotein Cholesterol to Highdensity Lipoprotein Cholesterol is Associated with Increased Risks of Hemorrhagic Transformation in Patients with Acute Ischemic Stroke
Current Neurovascular Research Biologics in Systemic Sclerosis
Current Pharmaceutical Biotechnology Neuroretinal Apoptosis as a Vascular Dysfunction in Diabetic Patients
Current Neuropharmacology Vascular Pharmacotherapy and Dementia
Current Vascular Pharmacology Meet the Editorial Board Member
Current Neuropharmacology Shut-Down of Translation, a Global Neuronal Stress Response:Mechanisms and Pathological Relevance
Current Pharmaceutical Design Current Evidence and Future Perspectives on Anti-platelet and Statin Pharmacotherapy for Patients with Symptomatic Peripheral Arterial Disease
Current Vascular Pharmacology Neuroprotective Effects of Ellagitannins: A Brief Review
Current Drug Targets CypA: A Potential Target of Tumor Radiotherapy and/or Chemotherapy
Current Medicinal Chemistry Role of Connexins and Pannexins in Ischemic Stroke
Current Medicinal Chemistry Endothelium in Aortic Aneurysm Disease: New Insights
Current Medicinal Chemistry Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus
Current Rheumatology Reviews